search
Back to results

CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) (CompARE)

Primary Purpose

Oropharyngeal Cancer

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Cisplatin
Durvalumab
Radiotherapy
Sponsored by
University of Birmingham
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Oropharyngeal Cancer focused on measuring Oropharyngeal cancer, HPV

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Oropharyngeal squamous cell carcinoma (OPSCC) in base of tongue and tonsil with a Multidisciplinary Team (MDT) recommendation for treatment with definitive concurrent chemoradiotherapy
  2. All OPC T4 or N3 (HPV+ and HPV-) OR all HPV -ve (negative) OPC T1-T4, N1-N3 or T3-4, N0 OR HPV +ve (positive) OPC T1-T4 with N2b-N3 nodes AND who are smokers ≥ 10 pack years current or previous smoking history
  3. Minimum life expectancy of 3 months
  4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  5. Adequate renal function, glomerular filtration rate (GFR) >50ml/min calculated using Cockcroft-Gault formula
  6. Adequate bone marrow function (absolute neutrophil count (ANC) ≥1.5 x 109/L, haemoglobin ≥9.0g/dL and platelets ≥100 x 109/L)
  7. Adequate liver function i.e. plasma bilirubin ≤1.5 times the upper limit of normal (ULN), and alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ≤2.5 x ULN
  8. Prothrombin time (PT) ≤1.5 x ULN or International Normalised Ratio (INR) ≤1. 5
  9. Magnesium ≥ lower limit of normal
  10. No cancers in previous 5 years, except basal cell carcinoma of skin and cervical intra-epithelial neoplasia (CIN)
  11. Aged 18-70
  12. Written informed consent given for the trial
  13. Surgically resectable disease if being randomised to all four arms
  14. Females must either be of non-reproductive potential (i.e. post-menopausal by history: ≥55 years old and no menses for ≥1 year without an alternative medical cause; or history of hysterectomy, or history of bilateral tubal ligation or history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry
  15. Willingness to comply with the protocol for the duration of the study, including undergoing treatment and scheduled visits and examinations including follow up

Exclusion Criteria:

  1. All T1-T2,N0 OPC (HPV +ve or HPV-ve)
  2. HPV positive patients who are:

    T1-T3, N0-N2c non-smokers T1-T3, N0-N2c smokers with ≤10 pack years or T1-T2, N0-N2a smokers with ≥10 pack years

  3. Unfit for chemoradiotherapy regimens
  4. Creatinine Clearance <50ml/min
  5. Treatment with any of the following, prior to randomisation:

    1. Any Investigational Medicinal Products (IMP) within 30 days
    2. Any other chemotherapy, immunotherapy or anticancer agents within 3 weeks
    3. Major surgery within 4 weeks
  6. History of allergic reactions to any of the IMPs and excipients used in this trial
  7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C, Human Immunodeficiency Virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
  8. Women who are pregnant or breast-feeding. Women of child- bearing potential must have a negative pregnancy test performed within 7 days prior to randomisation
  9. Men or women who are not prepared to practise methods of contraception of proven efficacy during treatment and for 6 months following the end of treatment
  10. Any condition that, in the opinion of the Investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results

    Additional Exclusion Criteria for Arm 5 only:

  11. Any previous treatment with PD-L or PD-L1 inhibitor, including durvalumab
  12. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid dose
  13. Active or prior documented autoimmune or inflammatory disorders including inflammatory bowel disease e.g. colitis or Crohn's disease, diverticulitis (with the exception of diverticulosis), celiac disease, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis). The following are exceptions to this criterion:

    • Patients with vitiligo or alopecia
    • Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement
    • Any chronic skin condition that does not require systemic therapy
    • Patients without active disease in the last 5 years may be included but only after consultation with the study physician
  14. Patients with an active non-infectious pneumonitis
  15. History of primary immunodeficiency
  16. History of allogeneic organ transplant
  17. Known history of previous clinical diagnosis of tuberculosis
  18. Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab. Inactivated viruses, such as those in the influenza vaccine, are permitted

Sites / Locations

  • St Luke's HospitalRecruiting
  • St James's HospitalRecruiting
  • Royal Devon and Exeter HospitalRecruiting
  • Leicester Royal Infirmary
  • Castle Hill Hospital
  • Colchester General HospitalRecruiting
  • Queen's HospitalRecruiting
  • Royal Preston HospitalRecruiting
  • James Cook University HospitalRecruiting
  • York HospitalRecruiting
  • Churchill HospitalRecruiting
  • Weston Park HospitalRecruiting
  • Freeman Hospital
  • Queen Elizabeth HospitalRecruiting
  • University Hospital Coventry
  • Newcross Hospital
  • Bradford Royal InfirmaryRecruiting
  • St James's University HospitalRecruiting
  • Aberdeen Royal InfirmaryRecruiting
  • Royal United HospitalRecruiting
  • Belfast City HospitalRecruiting
  • Bristol Haematology and Oncology CentreRecruiting
  • Addenbrooke's HospitalRecruiting
  • Velindre Cancer CentreRecruiting
  • Cheltenham General HospitalRecruiting
  • Western General HospitalRecruiting
  • Beatson West of Scotland Cancer CentreRecruiting
  • Aintree University Hospital
  • North Middlesex HospitalRecruiting
  • Christie HospitalRecruiting
  • Norfolk and Norwich University HospitalRecruiting
  • Nottingham City Hospital
  • Derriford HospitalRecruiting
  • Royal Shrewsbury HospitalRecruiting
  • Singleton HospitalRecruiting
  • Musgrove Park HospitalRecruiting
  • Torbay HospitalRecruiting
  • Clatterbridge Cancer CentreRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Arm 1 (control): chemoradiotherapy

Arm 5: Durvalumab + Arm 1

Arm Description

Concomitant chemoradiotherapy, 3-weekly cisplatin 100mg/m2 or weekly 40mg/m2 with Intensity Modulated Radiotherapy (IMRT) using 70 gray (Gy) in 35F(fractions) +/- neck dissection as indicated by clinical and radiological assessment 3-months post treatment. This is the international gold standard.

One dose of induction durvalumab 1500mg by intravenous (IV) infusion followed by arm 1 within four weeks. Within one-two weeks after the completion of arm 1, durvalumab 1500mg every four weeks will be initiated for a total of 6 months

Outcomes

Primary Outcome Measures

Patient Overall survival (OS)
defined as the interval in whole days between date of randomisation and date of death from any cause
Patient Event Free Survival (EFS)
defined as the interval in whole days between date of randomisation until date of progression/persistence/recurrence/death

Secondary Outcome Measures

Number of Acute (<3 months post-treatment) toxicity events experienced
Total number of acute (<3 months post-treatment) severe (grade 3-5) toxicity events experienced. Adverse events will be collected post-treatment and graded according to Common Terminology Criteria for Adverse Events (CTCAE).
Number of late (up to 2 years post-treatment) toxicity events experienced using CTCAE
Severe (grade 3-5) adverse events will be collected up to 2 years post randomisation, these events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 and version 3.0 for scoring mucositis.
Number of late (up to 2 years post-treatment) toxicity events experienced using RTOG
Late and severe toxicity events at 2 years post randomisation,will be collected and graded using Radiation Therapy Oncology Group (RTOG) Radiation Morbidity Scoring Criteria
Head and neck specific quality of life at 2 years post-randomisation using EORTC C30
Patients will complete the European Organisation for Research and Treatment of Cancer (EORTC) C30 questionnaire at baseline, at the end of treatment, and during the follow-up period until 2 years post-treatment
Head and neck specific Quality of Life at 2 years post-randomisation
Patients will complete the European Organisation for Research and Treatment of Cancer (EORTC) H&N35 questionnaire at baseline, at the end of treatment, and during the follow-up period until 2 years post-treatment
Swallowing outcomes assessed using MDADI Questionnaire at 24 months post-chemoradiotherapy
Patients will complete the M.D. Anderson Dysphagia Inventory (MDADI) Questionnaire at baseline, at the end of treatment, and during the follow-up period until 2 years post-treatment
Levels of Percutaneous Endoscopic Gastrostomy (PEG) use
PEG use will be assessed at baseline, throughout treatment and during 2 year follow-up period
Cost effectiveness of treatment as assessed using EuroQol Group (EQ-5D) questionnaire
Patients will complete the EuroQol Group (EQ-5D) questionnaire at baseline, at the end of treatment, and during the follow-up period until 2 years post-treatment
Surgical complication rates in each arm for patients who require a neck dissection at 4 months following the 3 month post-chemoradiotherapy assessment scan.
Surgical complication rates will be assessed at trial visits if a neck dissection is required at 4 months post-chemotherapy

Full Information

First Posted
August 13, 2018
Last Updated
December 14, 2022
Sponsor
University of Birmingham
Collaborators
AstraZeneca, Cancer Trials Ireland
search

1. Study Identification

Unique Protocol Identification Number
NCT04116047
Brief Title
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
Acronym
CompARE
Official Title
Phase III Randomised Controlled Trial Comparing Alternative Regimens for Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 2015 (Actual)
Primary Completion Date
December 2026 (Anticipated)
Study Completion Date
December 2030 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Birmingham
Collaborators
AstraZeneca, Cancer Trials Ireland

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
CompARE is a multicentre, phase III open-label randomised controlled trial using an adaptive, Multi-Arm, Multi-Stage (MAMS) design.
Detailed Description
The CompARE Trial examines alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer in an adult patient population. The aim is to assess whether escalated radiotherapy, adding surgery or immunotherapy will improve overall survival and quality of life in these patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Oropharyngeal Cancer
Keywords
Oropharyngeal cancer, HPV

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
785 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm 1 (control): chemoradiotherapy
Arm Type
Active Comparator
Arm Description
Concomitant chemoradiotherapy, 3-weekly cisplatin 100mg/m2 or weekly 40mg/m2 with Intensity Modulated Radiotherapy (IMRT) using 70 gray (Gy) in 35F(fractions) +/- neck dissection as indicated by clinical and radiological assessment 3-months post treatment. This is the international gold standard.
Arm Title
Arm 5: Durvalumab + Arm 1
Arm Type
Experimental
Arm Description
One dose of induction durvalumab 1500mg by intravenous (IV) infusion followed by arm 1 within four weeks. Within one-two weeks after the completion of arm 1, durvalumab 1500mg every four weeks will be initiated for a total of 6 months
Intervention Type
Drug
Intervention Name(s)
Cisplatin
Other Intervention Name(s)
CDDP, Platinol
Intervention Type
Drug
Intervention Name(s)
Durvalumab
Other Intervention Name(s)
MEDI-4736, Imfinzi
Intervention Type
Procedure
Intervention Name(s)
Radiotherapy
Primary Outcome Measure Information:
Title
Patient Overall survival (OS)
Description
defined as the interval in whole days between date of randomisation and date of death from any cause
Time Frame
from randomisation until date of death from any cause (follow-up until 8 years post-treatment)
Title
Patient Event Free Survival (EFS)
Description
defined as the interval in whole days between date of randomisation until date of progression/persistence/recurrence/death
Time Frame
From randomisation until date of progression/persistence/recurrence/death (follow-up until 8 years post-treatment)
Secondary Outcome Measure Information:
Title
Number of Acute (<3 months post-treatment) toxicity events experienced
Description
Total number of acute (<3 months post-treatment) severe (grade 3-5) toxicity events experienced. Adverse events will be collected post-treatment and graded according to Common Terminology Criteria for Adverse Events (CTCAE).
Time Frame
From date of randomisation until 2 year follow-up
Title
Number of late (up to 2 years post-treatment) toxicity events experienced using CTCAE
Description
Severe (grade 3-5) adverse events will be collected up to 2 years post randomisation, these events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 and version 3.0 for scoring mucositis.
Time Frame
From date of randomisation until 2 year follow-up
Title
Number of late (up to 2 years post-treatment) toxicity events experienced using RTOG
Description
Late and severe toxicity events at 2 years post randomisation,will be collected and graded using Radiation Therapy Oncology Group (RTOG) Radiation Morbidity Scoring Criteria
Time Frame
From date of randomisation until 2 year follow-up
Title
Head and neck specific quality of life at 2 years post-randomisation using EORTC C30
Description
Patients will complete the European Organisation for Research and Treatment of Cancer (EORTC) C30 questionnaire at baseline, at the end of treatment, and during the follow-up period until 2 years post-treatment
Time Frame
From date of randomisation until 2 year follow-up
Title
Head and neck specific Quality of Life at 2 years post-randomisation
Description
Patients will complete the European Organisation for Research and Treatment of Cancer (EORTC) H&N35 questionnaire at baseline, at the end of treatment, and during the follow-up period until 2 years post-treatment
Time Frame
From date of randomisation until 2 year follow-up
Title
Swallowing outcomes assessed using MDADI Questionnaire at 24 months post-chemoradiotherapy
Description
Patients will complete the M.D. Anderson Dysphagia Inventory (MDADI) Questionnaire at baseline, at the end of treatment, and during the follow-up period until 2 years post-treatment
Time Frame
From date of randomisation until 2 year follow-up
Title
Levels of Percutaneous Endoscopic Gastrostomy (PEG) use
Description
PEG use will be assessed at baseline, throughout treatment and during 2 year follow-up period
Time Frame
From date of randomisation until 2 year follow-up
Title
Cost effectiveness of treatment as assessed using EuroQol Group (EQ-5D) questionnaire
Description
Patients will complete the EuroQol Group (EQ-5D) questionnaire at baseline, at the end of treatment, and during the follow-up period until 2 years post-treatment
Time Frame
From date of randomisation until 2 year follow-up
Title
Surgical complication rates in each arm for patients who require a neck dissection at 4 months following the 3 month post-chemoradiotherapy assessment scan.
Description
Surgical complication rates will be assessed at trial visits if a neck dissection is required at 4 months post-chemotherapy
Time Frame
At 4 months following the 3 month post-chemoradiotherapy scan

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Oropharyngeal squamous cell carcinoma (OPSCC) in base of tongue and tonsil with a Multidisciplinary Team (MDT) recommendation for treatment with definitive concurrent chemoradiotherapy All OPC T4 or N3 (HPV+ and HPV-) OR all HPV -ve (negative) OPC T1-T4, N1-N3 or T3-4, N0 OR HPV +ve (positive) OPC T1-T4 with N2b-N3 nodes AND who are smokers ≥ 10 pack years current or previous smoking history Minimum life expectancy of 3 months Eastern Cooperative Oncology Group (ECOG) performance status 0-1 Adequate renal function, glomerular filtration rate (GFR) >50ml/min calculated using Cockcroft-Gault formula Adequate bone marrow function (absolute neutrophil count (ANC) ≥1.5 x 109/L, haemoglobin ≥9.0g/dL and platelets ≥100 x 109/L) Adequate liver function i.e. plasma bilirubin ≤1.5 times the upper limit of normal (ULN), and alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ≤2.5 x ULN Prothrombin time (PT) ≤1.5 x ULN or International Normalised Ratio (INR) ≤1. 5 Magnesium ≥ lower limit of normal No cancers in previous 5 years, except basal cell carcinoma of skin and cervical intra-epithelial neoplasia (CIN) Aged 18-70 Written informed consent given for the trial Surgically resectable disease if being randomised to all four arms Females must either be of non-reproductive potential (i.e. post-menopausal by history: ≥55 years old and no menses for ≥1 year without an alternative medical cause; or history of hysterectomy, or history of bilateral tubal ligation or history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry Willingness to comply with the protocol for the duration of the study, including undergoing treatment and scheduled visits and examinations including follow up Exclusion Criteria: All T1-T2,N0 OPC (HPV +ve or HPV-ve) HPV positive patients who are: T1-T3, N0-N2c non-smokers T1-T3, N0-N2c smokers with ≤10 pack years or T1-T2, N0-N2a smokers with ≥10 pack years Unfit for chemoradiotherapy regimens Creatinine Clearance <50ml/min Treatment with any of the following, prior to randomisation: Any Investigational Medicinal Products (IMP) within 30 days Any other chemotherapy, immunotherapy or anticancer agents within 3 weeks Major surgery within 4 weeks History of allergic reactions to any of the IMPs and excipients used in this trial Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C, Human Immunodeficiency Virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent Women who are pregnant or breast-feeding. Women of child- bearing potential must have a negative pregnancy test performed within 7 days prior to randomisation Men or women who are not prepared to practise methods of contraception of proven efficacy during treatment and for 6 months following the end of treatment Any condition that, in the opinion of the Investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results Additional Exclusion Criteria for Arm 5 only: Any previous treatment with PD-L or PD-L1 inhibitor, including durvalumab Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid dose Active or prior documented autoimmune or inflammatory disorders including inflammatory bowel disease e.g. colitis or Crohn's disease, diverticulitis (with the exception of diverticulosis), celiac disease, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis). The following are exceptions to this criterion: Patients with vitiligo or alopecia Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement Any chronic skin condition that does not require systemic therapy Patients without active disease in the last 5 years may be included but only after consultation with the study physician Patients with an active non-infectious pneumonitis History of primary immunodeficiency History of allogeneic organ transplant Known history of previous clinical diagnosis of tuberculosis Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab. Inactivated viruses, such as those in the influenza vaccine, are permitted
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Isla Humphreys
Email
CompARE@trials.bham.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Annabell Allen
Email
CompARE@trials.bham.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Prof Mehanna
Organizational Affiliation
University of Birmingham
Official's Role
Principal Investigator
Facility Information:
Facility Name
St Luke's Hospital
City
Dublin
ZIP/Postal Code
Dublin 6
Country
Ireland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sinead Brennan
First Name & Middle Initial & Last Name & Degree
Sinead Brennan
Facility Name
St James's Hospital
City
Dublin
ZIP/Postal Code
Dublin 8
Country
Ireland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cliona Grant
First Name & Middle Initial & Last Name & Degree
Cliona Grant
Facility Name
Royal Devon and Exeter Hospital
City
Exeter
State/Province
Devon
ZIP/Postal Code
EX2 5DW
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Hwang, MRCP FRCR
First Name & Middle Initial & Last Name & Degree
David Hwang
Facility Name
Leicester Royal Infirmary
City
Leicester
State/Province
East Midlands
ZIP/Postal Code
LE1 5WW
Country
United Kingdom
Individual Site Status
Active, not recruiting
Facility Name
Castle Hill Hospital
City
Cottingham
State/Province
East Yorkshire
ZIP/Postal Code
HU16 5JQ
Country
United Kingdom
Individual Site Status
Active, not recruiting
Facility Name
Colchester General Hospital
City
Colchester
State/Province
Essex
ZIP/Postal Code
CO4 5JL
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vivienne Loo, MRCP, FRCR
First Name & Middle Initial & Last Name & Degree
Vivienne Loo
Facility Name
Queen's Hospital
City
Romford
State/Province
Essex
ZIP/Postal Code
RM7 0AG
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amy Ward, MRCP, FRCR
First Name & Middle Initial & Last Name & Degree
Amy Ward
Facility Name
Royal Preston Hospital
City
Preston
State/Province
Lancashire
ZIP/Postal Code
PR2 9HT
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Arafat Mirza
First Name & Middle Initial & Last Name & Degree
Arafat Mirza, M
Facility Name
James Cook University Hospital
City
Middlesbrough
State/Province
North Yorkshire
ZIP/Postal Code
TS4 3BW
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eleanor Aynsley, MRCP, FRCR
First Name & Middle Initial & Last Name & Degree
Eleanor Aynsley
Facility Name
York Hospital
City
York
State/Province
North Yorkshire
ZIP/Postal Code
YO31 8HE
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Robin Prestwich, FRCR, PhD
First Name & Middle Initial & Last Name & Degree
Robin Prestwich
Facility Name
Churchill Hospital
City
Oxford
State/Province
Oxfordshire
ZIP/Postal Code
OX3 7LE
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ketan Shah, MRMCP,FRCR
First Name & Middle Initial & Last Name & Degree
Ketan Shah
Facility Name
Weston Park Hospital
City
Sheffield
State/Province
South Yorkshire
ZIP/Postal Code
S10 2SJ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Satya Garikipati
First Name & Middle Initial & Last Name & Degree
Satya Garikipati
Facility Name
Freeman Hospital
City
Newcastle Upon Tyne
State/Province
Tyne And Wear
ZIP/Postal Code
NE7 7DN
Country
United Kingdom
Individual Site Status
Active, not recruiting
Facility Name
Queen Elizabeth Hospital
City
Birmingham
State/Province
West Midlands
ZIP/Postal Code
B15 2TH
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrew Hartley, MRCP, FRCP
First Name & Middle Initial & Last Name & Degree
Andrew Hartley
Facility Name
University Hospital Coventry
City
Coventry
State/Province
West Midlands
ZIP/Postal Code
CV2 2DX
Country
United Kingdom
Individual Site Status
Active, not recruiting
Facility Name
Newcross Hospital
City
Wolverhampton
State/Province
West Midlands
ZIP/Postal Code
WV10 OQP
Country
United Kingdom
Individual Site Status
Active, not recruiting
Facility Name
Bradford Royal Infirmary
City
Bradford
State/Province
West Yorkshire
ZIP/Postal Code
BD9 6RJ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karen Dyker
First Name & Middle Initial & Last Name & Degree
Karen Dyker
Facility Name
St James's University Hospital
City
Leeds
State/Province
West Yorkshire
ZIP/Postal Code
LS9 7TF
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mehmet Sen, MRCP, MD
First Name & Middle Initial & Last Name & Degree
Mehmet Sen
Facility Name
Aberdeen Royal Infirmary
City
Aberdeen
ZIP/Postal Code
AB25 2ZN
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rafael Moleron, MBBS, MD
First Name & Middle Initial & Last Name & Degree
Rafael Moleron
Facility Name
Royal United Hospital
City
Bath
ZIP/Postal Code
BA1 3NG
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emma de Winton
First Name & Middle Initial & Last Name & Degree
Emma de Winton
Facility Name
Belfast City Hospital
City
Belfast
ZIP/Postal Code
BT9 7AB
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fionnuala Houghton, MRCP, FRCR
First Name & Middle Initial & Last Name & Degree
Fionnuala Houghton
Facility Name
Bristol Haematology and Oncology Centre
City
Bristol
ZIP/Postal Code
BS2 8ED
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Georgina Casswell
First Name & Middle Initial & Last Name & Degree
Georgina Casswell
Facility Name
Addenbrooke's Hospital
City
Cambridge
ZIP/Postal Code
CB2 0QQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Richard Benson
First Name & Middle Initial & Last Name & Degree
Richard Benson
Facility Name
Velindre Cancer Centre
City
Cardiff
ZIP/Postal Code
CF14 2TL
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Richard Webster
First Name & Middle Initial & Last Name & Degree
Richard Webster
Facility Name
Cheltenham General Hospital
City
Cheltenham
ZIP/Postal Code
GL53 7AN
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Warren Grant
First Name & Middle Initial & Last Name & Degree
Warren Grant
Facility Name
Western General Hospital
City
Edinburgh
ZIP/Postal Code
EH4 2XU
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Devraj Srinivasan, MRCP, FRCR
First Name & Middle Initial & Last Name & Degree
Devraj Srinivasan
Facility Name
Beatson West of Scotland Cancer Centre
City
Glasgow
ZIP/Postal Code
G12 0YN
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stefano Schipani
First Name & Middle Initial & Last Name & Degree
Stefano Schipani
Facility Name
Aintree University Hospital
City
Liverpool
ZIP/Postal Code
L9 7AL
Country
United Kingdom
Individual Site Status
Active, not recruiting
Facility Name
North Middlesex Hospital
City
London
ZIP/Postal Code
N18 1QX
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna Thompson, MRCP, FRCR
First Name & Middle Initial & Last Name & Degree
Anna Thompson
Facility Name
Christie Hospital
City
Manchester
ZIP/Postal Code
M20 4BX
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lip Wai Lee
First Name & Middle Initial & Last Name & Degree
Lip Wai Lee
Facility Name
Norfolk and Norwich University Hospital
City
Norwich
ZIP/Postal Code
NR4 7UY
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dinos Geropantas, MBBS, CCT
First Name & Middle Initial & Last Name & Degree
Dinos Geropantas
Facility Name
Nottingham City Hospital
City
Nottingham
ZIP/Postal Code
NG5 1PB
Country
United Kingdom
Individual Site Status
Active, not recruiting
Facility Name
Derriford Hospital
City
Plymouth
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rebecca Goranova, MRCP,FRCR
First Name & Middle Initial & Last Name & Degree
Rebecca Goranova
Facility Name
Royal Shrewsbury Hospital
City
Shrewsbury
ZIP/Postal Code
SY3 8XQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura Pettit, MRCP,FRCR
First Name & Middle Initial & Last Name & Degree
Laura Pettit
Facility Name
Singleton Hospital
City
Swansea
ZIP/Postal Code
SA2 8QA
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Russell Banner, MRCP,FRCR
First Name & Middle Initial & Last Name & Degree
Russell Banner
Facility Name
Musgrove Park Hospital
City
Taunton
ZIP/Postal Code
TA1 5DA
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Petra Jankowska, MRCP, FRCR
First Name & Middle Initial & Last Name & Degree
Petra Jankowska
Facility Name
Torbay Hospital
City
Torquay
ZIP/Postal Code
TQ2 7AA
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jonathan Chambers, MRCP, FRCR
First Name & Middle Initial & Last Name & Degree
Jonathan Chambers
Facility Name
Clatterbridge Cancer Centre
City
Wirral
ZIP/Postal Code
CH63 4JY
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Caroline Brammer, MRCP,FRCP
First Name & Middle Initial & Last Name & Degree
Caroline Brammer

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

We'll reach out to this number within 24 hrs